Vylor

2026 Investor Day

Built on genetics. Powered by innovation.

September 15, 2026

Vylor

Welcome & Opening Remarks

Kimberly Booth

VICE PRESIDENT, INVESTOR RELATIONS AND FP&A

Legal Disclaimers

Forward-Looking Statements

This presentation contains certain estimates and forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and may be identified by their use of words like "plans," "expects," "will," "assumes," "anticipates," "believes," "intends," "projects," "targets," "poised," "launch," "positioned," "committed," "estimates," "outlook," or other words of similar meaning. All statements that address expectations or projections about the future, including statements about 'our financial results or outlook; strategy for growth; product development; pipeline value estimates; regulatory approvals; market position; industry size and growth estimates; assumptions regarding planted acreage, commodity prices, currency rates, and market conditions; capital allocation strategy; licensing and royalty income targets; liquidity; sustainability targets and initiatives; the anticipated benefits of acquisitions, restructuring actions, or cost savings initiatives; the anticipated benefits, impacts, and timing of the proposed spin-off; and the outcome of contingencies, such as litigation and environmental matters, are forward-looking statements.

Forward-looking statements and other estimates are based on certain assumptions and expectations of future events which may not be accurate or realized. Forward-looking statements and other estimates also involve risks and uncertainties, many of which are beyond our control. While the list of factors presented below is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on our business, results of operations and financial condition. Some of the important factors that could cause our actual results to differ materially from those projected in any such forward-looking statements include: (i) failure to obtain or maintain the necessary regulatory approvals for some of the company's products; (ii) failure to successfully develop and commercialize the company's pipeline; (iii) effect of the degree of public understanding and acceptance or perceived public acceptance of the company's biotechnology and other agricultural products; (iv) failure to comply with competition and antitrust laws; (v) effect of changes in agricultural and related policies of governments and international organizations; (vi) costs of complying with evolving regulatory requirements and the effect of actual or alleged violations of environmental laws or permit requirements; (vii) effect of climate change and unpredictable seasonal and weather factors; (viii) effect of competition in our industry; (ix) competitor's establishment of an intermediary platform for distribution of our products; (x) risks related to recent funding and staff reductions at U.S. government agencies; (xi) risk related to geopolitical and military conflict; (xii) effect of volatility in our input costs; (xiii) risks related to our global operations; (xiv) effect of industrial espionage and other disruptions to our supply chain, information technology or network systems; (xv) risks related to environmental, litigation, and other commitments and contingencies; (xvi) impact of our dependence on third parties with respect to certain of its seed production or licenses and commercialization; (xvii) failure of our customers to pay their debts to us, including customer financing programs; (xviii) failure to effectively manage acquisitions, divestitures, alliances, restructurings, cost savings initiatives, and other portfolio actions; (xix) risks related to our use of artificial intelligence and machine learning technologies; (xx) failure to raise capital through the capital markets or short-term borrowings on terms acceptable to us; (xxi) risks related to pandemics or epidemics; (xxii) capital markets sentiment towards sustainability matters; (xxiii) our intellectual property rights or defense against intellectual property claims asserted by others; (xxiv) effect of counterfeit products; (xxv) our dependence on intellectual property cross-license agreements; (xxvi) risks related to our common stock; and (xxvii) risks related to the spin-off, including, but not limited to, whether the objectives of the spin-off will be achieved; the terms, structure, benefits and costs of any action or transaction resulting from the spin-off; the timing of the spin-off or related action and whether the spin-off will be consummated at all; the risk that the spin-off could divert the attention and time of the company's management; the risk of any unexpected costs or expenses resulting from the spin-off process or the spin-off itself; and the risk of any litigation as a result of, or relating to, the spin-off.

Additionally, there may be other risks and uncertainties that Vylor is unable to currently identify or that Vylor does not currently expect to have a material impact on its business. Where, in any forward-looking statement or other estimate, an expectation or belief as to future results or events is expressed, such expectation or belief is based on the current plans and expectations of Vylor's management and expressed in good faith and believed to have a reasonable basis, but there can be no assurance that the expectation or belief will result or be achieved or accomplished. Vylor disclaims and does not undertake any obligation to update or revise any forward-looking statement, except as required by applicable law. A detailed discussion of some of the significant risks and uncertainties which may cause results and events to differ materially from such forward-looking statements is included in the section titled "Risk Factors" in Corteva's annual and quarterly reports filed on Forms 10-K and 10-Q and the preliminary registration statement on Form 10 of Vylor, as amended.

Vylor Unaudited Pro Forma Financial Information and Management Adjustments

The following presentation presents the pro forma results of Vylor, after giving effect to events that are (1) directly attributable to the Pro Forma Transactions including the disposition of Corteva's Crop Protection Business, the effect of our anticipated capital structure following the spin-off, the pro-rata distribution of our issued and outstanding common stock by Corteva in connection with the spin-offs, and the impact of the Separation and Distribution Agreement, Tax Matters Agreement, Employee Matters Agreement, Transition Services Agreements, Commercial Agreements, Intellectual Property Matters Agreement and other ancillary agreements between Vylor and New Corteva and the provisions contained therein; (2) factually supportable and (3) with respect to the pro forma statements of income, expected to have a continuing impact on the consolidated results. Refer to Vylor's preliminary Form 10 registration statement (and subsequent amendments thereto), which can be found on the investors section of the Corteva website, for further details on the above transactions. The pro forma financial statements were prepared in accordance with Article 11 of Regulation S-X, and are presented for informational purposes only, and do not purport to represent what the results of operations would have been had the above actually occurred on the dates indicated, nor do they purport to project the results of operations for any future period or as of any future date.

Legal Disclaimers

Vylor Unaudited Pro Forma Financial Information and Management Adjustments (continued)

This presentation also reflects management adjustments that would not be included in the pro forma financial statements prepared in accordance with Article 11 of Regulation S-X. These adjustments reflect management's estimates of certain incremental costs and cost savings associated with Vylor operating as an independent public company that are not reflected in Pro Forma Operating EBITDA. These estimates are based on assumptions management believes are reasonable as of the date of this presentation. Actual costs and savings may differ materially from these estimates, including as a result of the timing or extent to which anticipated cost savings are realized.

Regulation G (Non-GAAP Financial Measures)

This presentation includes information that does not conform to U.S. GAAP and are considered non-GAAP measures. These measures may include operating EBITDA, operating EBITDA margin, adjusted pro forma operating EBITDA, adjusted pro forma operating EBITDA margin, free cash flow, and free cash flow conversion. Management uses these measures internally for planning and forecasting, including allocating resources and evaluating incentive compensation. Management believes that these non-GAAP measures best reflect the ongoing performance of the Company during the periods presented and provide more relevant and meaningful information to investors as they provide insight with respect to ongoing operating results of the Company and a more useful comparison of year over year results.

These non-GAAP measures supplement the Company's U.S. GAAP disclosures and should not be viewed as an alternative to U.S. GAAP measures of performance. Furthermore, such non-GAAP measures may not be consistent with similar measures provided or used by other companies. This data should be read in conjunction with the Company's preliminary registration statement on Form 10 filing (and subsequent amendments thereto). Reconciliations of historical non-GAAP measures to U.S. GAAP are provided at the end of this presentation.

Vylor does not provide reconciliations of certain forward-looking non-GAAP financial measures to their most directly comparable U.S. GAAP financial measures because Vylor is unable to predict with reasonable certainty and without unreasonable effort certain items necessary to provide such reconciliations. These items may include, among others, restructuring and separation-related charges, certain pension items, asset impairments, acquisition- or divestiture-related items, and other significant items. These items are uncertain, depend on various factors and could have a significant impact, individually or in the aggregate, on the corresponding U.S. GAAP financial measures. Beginning January 1, 2020, the Company presents accelerated prepaid royalty amortization expense as a significant item. Accelerated prepaid royalty amortization represents the non-cash charge associated with the recognition of upfront payments made to Monsanto in connection with the Company's non-exclusive license in the United States and Canada for Monsanto's Genuity® Roundup Ready 2 Yield® and Roundup Ready 2 Xtend® herbicide tolerance traits. Due to the ramp-up of Enlist E3™, the Company significantly reduced the volume of products with the Roundup Ready 2 Yield® and Roundup Ready 2 Xtend® herbicide tolerance traits beginning in 2021, with expected minimal use of the trait platform thereafter.

Pro forma operating EBITDA is defined as pro forma earnings (loss) (i.e., pro forma income (loss) from continuing operations before income taxes) before interest, depreciation, amortization, non-operating benefits (costs), foreign exchange gains (losses), and net unrealized gain or loss from mark-to-market activity for certain foreign currency derivative instruments that do not qualify for hedge accounting, excluding the impact of significant items and separation costs. Non-operating benefits (costs) consists of non-operating pension and OPEB credits (costs). Net unrealized gain or loss from mark-to market activity for certain foreign currency derivative instruments that do not qualify for hedge accounting represents the non-cash net gain (loss) from changes in fair value of certain undesignated foreign currency derivative contracts. Upon settlement, which is within the same calendar year of execution of the contract, the realized gain (loss) from the changes in fair value of the non-qualified foreign currency derivative contracts will be reported in the relevant non-GAAP financial measures, allowing quarterly results to reflect the economic effects of the foreign currency derivative contracts without the resulting unrealized mark to fair value volatility. Pro forma Operating EBITDA margin is defined as pro forma Operating EBITDA as a percentage of net sales. Adjusted Pro Forma Operating EBITDA represents Pro Forma Operating EBITDA, further adjusted to reflect management's estimates of certain incremental cost savings associated with operating Vylor as an independent public company that are not reflected in the Pro Form Operating EBITDA. Adjusted Pro Forma Operating EBITDA margin is defined as Adjusted Pro Forma Operating EBITDA as a percentage of net sales. Management believes this measure provides useful supplemental information regarding the expected cost structure of Vylor as an independent public company. The management adjustments are based on estimates and assumptions and actual costs and savings may differ materially from those reflected in the adjustments. As used in this presentation, "operating EBITDA" presented in forward-looking periods refers to Pro Forma Operating EBITDA, unless otherwise noted. Historical "operating EBITDA" figures shown for FY 2025 refer to Adjusted Pro Forma Operating EBITDA, unless otherwise noted.

The Company also uses Free Cash Flow and Free Cash Flow Conversion as non-GAAP measures to evaluate and discuss its liquidity position and ability to generate cash. Free Cash Flow is defined as cash provided by (used for) operating activities – continuing operations, less capital expenditures. Free Cash Flow Conversion is defined as Free Cash Flow divided by Adjusted Pro Forma Operating EBITDA. We believe that Free Cash Flow and Free Cash Flow Conversion provide investors with meaningful information regarding the Company's ongoing ability to generate cash through core operations, and our ability to service our indebtedness, pay dividends (when declared), make share repurchases, and meet our ongoing cash needs for our operations. Vylor is not able to reconcile its forward-looking Free Cash Flow Conversion non-GAAP financial measure to its most comparable U.S. GAAP financial measure, as it is unable to predict with reasonable certainty Operating EBITDA due to items outside of the company's control, which includes the same Significant Items noted above, without unreasonable effort.

Legal Disclaimers

No Offer or Solicitation

This presentation does not constitute a solicitation of a proxy, consent or authorization with respect to any securities of Vylor. This presentation also does not constitute an offer to sell or the solicitation of an offer to buy securities, nor will there be any sale of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities will be made except by means of a prospectus meeting the requirements of the Securities Act of 1933, as amended, or an exemption therefrom.

Industry and Share Data

This presentation includes information and statistics regarding market participants in the sectors in which Vylor competes and other industry data which was obtained from third-party sources, including reports by market research firms, governmental agencies, intergovernmental organizations, industry publications, academic research and publicly available company information. While we believe the third-party market and industry data included in this presentation are generally reliable, the market and industry data have not been independently verified by us and involve risks and uncertainties and are subject to change based on various factors. This presentation also includes data derived from Vylor's internal research, testing, and analysis, which has not been independently verified and involves estimates and assumptions that are subject to change.

Trademarks

This presentation may contain trademarks, service marks, trade names and copyrights of other companies, which are the property of their respective owners. Solely for convenience, some of the trademarks, service marks, trade names and copyrights referred to in this presentation may be listed without the TM, SM © or ® symbols, but we will assert, to the fullest extent under applicable law, the rights of the applicable owners, if any, to these trademarks, service marks, trade names and copyrights. Certain trademarks used in this presentation are the property of Corteva, Inc. and will be owned by or licensed to Vylor following the completion of the spin-off, as described in Vylor's Form 10 registration statement.

Projected Financial Information

This presentation contains financial forecasts, which were prepared in good faith by Vylor on a basis believed to be reasonable. Certain financial measures and targets in this presentation are non-GAAP measures, as described in the Regulation G disclaimer included elsewhere in this presentation. The pro forma financial information has been prepared in accordance with Article 11 of Regulation S-X. The financial projections in this presentation have not been audited or reviewed by Vylor's independent auditors. These projections are for illustrative purposes only and should not be relied upon as being necessarily indicative of future results. See the Forward-Looking Statements disclaimer included elsewhere in this presentation for a discussion of risks and uncertainties that may cause actual results to differ materially.

Investor day webcast agenda

TIME	AGENDA ITEM	SPEAKER(S)	DURATION
9:00–9:05 AM ET	Welcome, safe harbor language	Kim Booth | VICE PRESIDENT, INVESTOR RELATIONS AND FP&A	5 MINS
9:05–9:30 AM ET	CEO address — strategy overview	Chuck Magro | CHIEF EXECUTIVE OFFICER	25 MINS
9:30–9:55 AM ET	Growth through innovation	Sam Eathington | CHIEF TECHNOLOGY OFFICER	25 MINS
9:55–10:20AM ET	Positioned for success	Judd O'Connor | CHIEF COMMERCIAL AND OPERATIONS OFFICER	25 MINS
10:20–10:35 AM ET	Break		15 MINS
10:35–10:55 AM ET	Financial framework	David Johnson | CHIEF FINANCIAL OFFICER	20 MINS
10:55–11:25 AM ET	Q&A session	All speakers, moderated by Kim Booth	30 MINS
11:25–11:30 AM ET	CEO closing remarks	Chuck Magro | CHIEF EXECUTIVE OFFICER	5 MINS

Vylor

Vylor

Introducing Vylor

Chuck Magro

CHIEF EXECUTIVE OFFICER

CEO perspective

“Vylor is the only global pure-play ag genetics platform.”

Chuck Magro, CEO

Vylor

An unrivaled innovator with a century-long track record

Pioneer® is the #1 U.S. corn and soybean brand

300+
Products launched annually

~27%
Operating EBITDA margin[2] (2026E)

~10% (~2X peer avg ROI)
Annual R&D investment as a percent of sales

~$19B
Pipeline value (estimated peak NTR[3])

~8,000
Patents

2025 revenue: ~$10B[1]

REVENUE BY CROP

Established platforms with diversified mix



REVENUE BY REGION

Global reach across ~70 countries



1. 2025 Net sales are stated on an as reported basis for the Seed segment of Corteva.
2. Represents management's forward-looking estimates and is presented on a pro forma basis giving effect to the transactions described in the Form 10. 2026 Operating EBITDA is a non-GAAP financial measure. See slide 4 regarding forward-looking non-GAAP measures. See appendix for non-GAAP reconciliations.
3. Estimated peak net trade revenue pipeline value by the end of 2039.
4. Oilseeds includes sunflower and canola.
5. Other includes cotton, mustard, sorghum, wheat, rice, inoculants, and millet.
6. Europe, Middle East, and Africa.
7. Includes U.S. & Canada.

Vylor

What we have delivered

Key accomplishments since 2020

- Advantaged routes-to-market with the #1 U.S. corn and soybean brand
- Launched over 1,700 new products (hybrids and varieties)
- Improved net licensing position by >$550M
- Disciplined focus on productivity drove earnings benefits of ~$570M
- Cumulative $4.25B R&D investment



Foundation for next phase: pipeline + licensing + productivity

1. 2020 and 2025 Net sales, Operating EBITDA, and Operating EBITDA margin are stated on an as reported basis for the Seed segment of Corteva.

Foundational drivers of agriculture technology remain intact



Food security

Growing population with ~2B more people in the next 25 years[1]

Changing weather patterns

~5–25% potential reduction in crop yields in key regions from 2°C increase in global temperatures[2]

Up to 40% of crop production globally lost to pests and diseases[3]

Energy transition

Global biofuels demand is on track to reach ~80 billion gallons annually by 2040

Driven by structural growth in renewable diesel and sustainable aviation fuel, with advanced feedstocks supplying more than 60% of total volumes[4]

Need to feed more people | Food is getting harder to grow | Biofuels demand expected to double in next decade

Vylor

1. United Nations, Department of Economic and Social Affairs, Population Division (2024). World Population Prospects 2024, Online Edition.
2. Jägermeyr, J., Müller, C., Ruane, A.C. et al. Climate impacts on global agriculture emerge earlier in new generation of climate and crop models. Nat Food 2, 873–885 (2021); assumes no technology changes or improvements.
3. Food and Agriculture Organization of the United Nations. (2021, June 2). Climate change fans spread of pests and threatens plants and crops, new FAO study.
4. S&P Global Commodity Insights. Fueling the Future – Biofuels driving progress on net zero (February 2024).

What sets Vylor apart

1 Strongest genetic foundation

Global germplasm library supports yield leadership and a structural advantage.

- 100 years of germplasm experience
- Doubling rate of genetic gain with new technology deployment

2 Innovation at scale

Advanced R&D and production accelerates genetic gain through breeding, gene editing, analytics and AI.

- 137 R&D facilities
- 60 production facilities
- 19,000 seed production grower network

3 Faster commercialization

PIONEER® HUNDRED YEARS

Integrated routes-to-market deliver innovation directly to growers at scale.

- ~90% customer retention[1]
- ~4,000 field employees & sales representatives[1]

Together, these advantages create compounding innovation, growth and returns

Vylor

1. North America Pioneer and regional brands.

A top-tier global seed and genetics company with proven leadership and depth

Vylor's regional leadership positions[1]

CORN	**#1 North America**	#2 Latin America	**#1 EMEA**	**#1 APAC[2]**
SOYBEAN	**#1 North America**	#6 Latin America		
WHEAT	#4 North America			
CANOLA	#2 North America	#4 EMEA	**#1 APAC[2]**	
COTTON	#2 North America			
SUNFLOWER	#2 EMEA			
SORGHUM	**#1 North America**	**#1 Latin America**		

Strong market presence across core crops with leadership positions in key geographies

CORN	SOYBEANS	WHEAT
7 Differentiated Technology Platforms launch[3] by 2035 across markets representing ~90% of our corn business[1]	**4** Differentiated Technology Platforms launch[3] by 2035 across markets representing ~95% of our soybean business[1]	**1** Differentiated Technology Platform launch[3] in 2027 with North America Hard Red Winter
NORTH AMERICA		
• Next Gen Above • Next Gen Above & Below	• Herbicide Tolerance	• Hard Red Winter Hybrid • Soft Red Winter Hybrid • Hard Red Spring Hybrid
LATIN AMERICA		
• ABRANVO™ • Next Gen Above	• Next Gen Lep • 1st Gen Asian Soybean Rust	
GLOBAL LEVERAGED TECHNOLOGY PLATFORMS		
• Yield & Yield Stability • Multi-Disease Resistance • Reduced Stature Corn	• Multi-Disease Resistance	• XPEDITE™ Hybrid Wheat Breeding System

1. Market share and ranks based on branded business. Source: Agrowin Seed 3rd-party market research.
2. APAC excluding China.
3. Launch pending applicable global regulatory reviews and completion of field testing.

Vylor

Vylor performance acceleration framework



Expand into future value pools

- Largest ag gene editing patent estate outside China
- Technology licensing beyond core crops
- Addressable market expands well beyond today's seed business

Scale our growth platforms

- Shift from technology buyer to technology owner
- Hybrid wheat creates an entirely new category
- Biofuels creates a new demand engine
- Gene-edited disease resistance moves into commercial scale

Foundational value engine

- Corn pipeline reinforces competitive advantage
- Expanding soybean leadership position
- Increasing value capture from proprietary traits and genetics, including novel Yield & Yield Stability (YYS) trait

Largest innovation cycle in company history, built on the foundation of enduring competitive advantages

Vylor

Licensing unlocks incremental value

Americas: **$4B** licensing market opportunity

Established platform with diversified mix generating ~$0.4B in licensing revenue in 2026

North America

~$2B



Latin America

~$2B



VALUE TO INDUSTRY

- ✓ Increased choice for farmers and independent seed companies
- ✓ Open ecosystems and collaboration
- ✓ Expanded scope beyond Americas and beyond row crops

VALUE TO VYLOR

- ✓ Expanded market access beyond branded business
- ✓ Broad adoption of Vylor technology
- ✓ Incremental profit for our leading technology

Transitioning to royalty positive in 2026; targeting $1B net licensing income position by 2035

Vylor

Hybrid Wheat: the next $1B platform

Globally important crop; small in Vylor today; proprietary technology expected to scale to $1B by 2040

A century of U.S. yield growth



Wheat opportunity

- World's most widely cultivated crop — nearly 550 million acres globally[1]
- Cornerstone of food security — ~20% of the world's caloric intake[1]
- World's most traded ag crop — ~$50B global trade market[1]
- The last major under-innovated row crop
- Fragmented end-markets and diverse geographic competition

Why Vylor can win

- Driven by novel non-GMO, non-CMS proprietary hybrid breeding system
- Offers ~10–20% higher yields compared to conventional varieties[2] — a significant breakthrough in productivity
- Captures value through Pioneer branded sales along with licensing opportunities in additional markets

Launching US Hard Red Winter wheat in 2027, targeting $500M in revenue by 2035; $1B by 2040

Vylor

1. Source: USDA.
2. Internal yield testing on launch hybrids: 3 years (2024, 2025, 2026) of testing.

The transformational potential of gene editing

Protect against disease & pests

- Disease & pest resistance
- Climate resilience
- Input efficiency

Increase crop output

- Higher yield
- Harvest efficiency
- New applications

Withstand stresses

- Expanded shelf-life
- Transport durability

Deliver consumer benefits

- Convenience, ease of use
- Nutrition and allergens

GOOD FOR FARMERS → **GOOD FOR PLANET** → **GOOD FOR CONSUMERS**

CORN

~$7.5B	Lost to "Big 4" diseases in the last 5 years[1]
~4M	Acres lost to 4 top diseases in 2025[1]
> $1B	Spent on fungicide treatment for corn globally every year[2]

With MDR | Without MDR

BANANAS

~$125B	Global retail/market value — highly produced and consumed[3]
> 5B	Bananas thrown away annually in the U.S.[4]
> 60%	Exported bananas go to waste prior to reaching consumers[5]

Standard Cavendish | Tropic Reduced Browning

Precise changes in the plant's own DNA has the potential to create new opportunities throughout the value chain

1. Crop Protection Network data on Top 4 diseases: Gray leaf spot, Northern corn leaf blight, Southern rust, Anthracnose stalk rot and top dieback; does not include tar spot.
2. Internal Corteva Analysis – 2022 – 2025.
3. Internal Corteva estimates.
4. Gunders, Dana. "Op-ed: 5 billion bananas get thrown away each year — how reducing food waste can help solve the climate crisis." The Chicago Tribune. April 9, 2021. https://www.chicagotribune.com/2021/04/09/op-ed-5-billion-bananas-get-thrown-away-each-year-how-reducing-food-waste-can-help-solve-the-climate-crisis/.
5. Tropic's Non-Browning Gene-Edited Banana Cleared for Production in the Philippines. https://tropic.bio/tropics-non-browning-gene-edited-banana-cleared-for-production-in-the-philippines/.

Vylor

Disciplined capital allocation strategy

Share repurchases

- Preferred method to return capital
- Intention to authorize $3B share repurchase program in 4Q

M&A

- Focus on adjacencies / build from core
- Disciplined financial return criteria

Capital investment

- Fund high ROI projects
- Support organic growth in attractive end markets

Sustainable and growing dividend

- Continued positive outlook
- Dividend growth over time with earnings

Committed to investing into R&D at ~10% of sales to ensure robust pipeline

Vylor

CapEx Dividend Share Repurchase and M&A

Vylor growth algorithm

This decade...

2027–2029 TARGETS

~3–4%	Net sales[1] CAGR
~7–8%	Operating EBITDA[1] CAGR at midpoint
~30% margin	2029 Operating EBITDA[1] margin at midpoint
~60% (EBITDA basis)	Avg. free cash flow conversion[1]
~$1B	Annual share repurchase target (excluding significant M&A)

Next decade...

12	technology platforms launching in next 10 years
$2B	incremental corn revenues by 2035, including licensing
$0.5B	incremental soybean revenues by 2035, including licensing
$1B	hybrid wheat revenues by 2040, including licensing
YYS	industry's first Yield & Yield Stability trait in corn
MDR	gene-edited Multi-Disease Resistance in corn and soybeans
$19B	estimated peak net trade revenue pipeline value[2]

Vylor

1. Represent management's forward-looking estimates and are presented on a pro forma basis giving effect to the transactions described in the Form 10. Operating EBITDA, Operating EBITDA Margin, and Free Cash Flow Conversion are non-GAAP financial measures. See slide 4 regarding forward-looking non-GAAP measures. See appendix for non-GAAP reconciliations.
2. Estimated peak net trade revenue pipeline value by the end of 2039.

Vylor's management team

Chuck Magro

Chief Executive Officer

Nutrien
Agrium
CORTEVA agriscience

David Johnson

Chief Financial Officer

Atkore
EATON
CORTEVA agriscience

Judd O'Connor

Chief Commercial and Operations Officer

PIONEER
DUPONT
CORTEVA agriscience

Sam Eathington

Chief Technology Officer

MONSANTO
THE CLIMATE CORPORATION
CORTEVA agriscience

Audrey Grimm

Chief People Officer

DOW
CORTEVA agriscience

Brian Lutz

Chief Digital and Information Officer

BAYER
THE CLIMATE CORPORATION
CORTEVA agriscience

Jennifer Johnson

Chief Legal Officer

DUPONT
iff
CORTEVA agriscience

Key takeaways

1

Unique agriculture and technology platform powered by intellectual property

2

Multiple innovation-driven growth platforms

3

Disciplined execution driving long-term value creation

4

Proven leadership reinforcing compelling growth opportunity

Vylor

Innovation & proprietary technology unlocks growth

Sam Eathington

CHIEF TECHNOLOGY OFFICER

Vylor's leadership advantage in innovation

1926-2019 A first-mover legacy

$10B[1]	First commercial hybrid corn in Midwest
4x Expansion	First winter nursery program for year-round breeding
10x Larger	First to use computer for breeding data analysis
30k Genes	First genomics program in corn
2x Durability	First integrated refuge management biotech solution for farmers

2020-2025 A track-record of delivery

1,700+	New hybrids and varieties launched in 10 crops
5	Technology platforms launched in corn and soybean
5%+	Improvement in genetic yield potential
World Records	Yields set by our corn and soybean products
300+	Biotech regulatory approvals
3,100+	Germplasm and Biotechnology patents

TODAY-NEXT DECADE Unlocking Vylor's bold future...

12	Technology platforms to be launched in the next decade
First	Industry's first biotech Yield & Yield Stability (YYS) trait in corn
Hybrid Wheat	Novel & proprietary – Xpedite™ hybrid wheat breeding system
7 New	Novel insect control genes
New Protection	Gene-edited Multi-Disease Resistance (MDR) in corn and soybean
Global Expansion	Gene editing & Genlytix™ ecosystem enabling expansion in where to play

1. 2025 Net sales are stated on an as reported basis for the Seed segment of Corteva.

Vylor's industry-leading innovation solves increasing production challenges

INSECTS

WEEDS

DISEASES

ABIOTIC STRESSES



Up to **$290B**[1] / Annual global crop production loss to these challenges

INDUSTRY-LEADING INNOVATION PILLARS

Gene editing

Industry-leading science portfolio focused on improvement in core and adjacent crops

Biotechnology

Industry-leading portfolio of traits designed to protect and preserve on-farm productivity

Breeding

World's most elite germplasm pool, built over a century, underpins performance in 10 crops globally



Vylor

1. Food and Agriculture Organization of the United Nations: Plant Production and Protection Division report (2022).

Vylor's innovation portfolio enables current & future value

Vylor will launch 12 technology platforms in the next decade

GROWING VALUE

Vylor's innovation pipeline is shaped by our science leadership

~$19B
Estimated peak net trade revenue[1]

>55%
Accretive growth

$4B
Added peak NTR pipeline value since 2023

NEXT GENERATION TECHNOLOGY

Vylor will deliver never-before-seen science

Insect control
7 novel genes

Weed control
2 novel genes

Disease
14 Multi-Disease Resistance genes

Extreme conditions
Yield & Yield Stability (YYS)
Reduced Stature Corn (RSC)

NEW PROPRIETARY PRODUCTS

Vylor's industry-leading germplasm and portfolio enables growth in branded and licensing businesses

OVER THE NEXT DECADE

Corn	Soybean	Wheat
● Next Gen Above NA	● Herbicide Tolerance	• Hard Red Winter Hybrid
● Next Gen Above & Below NA	● Next Gen Lep LATAM	• Soft Red Winter Hybrid
● ABRANVO™ LATAM	● 1st Gen Asian Soybean Rust LATAM	• Hard Red Spring Hybrid
● Next Gen Above LATAM		

Leveraged Technology Platforms

● Yield & Yield Stability	● Multi-Disease Resistance	● XPEDITE™ Hybrid Wheat Breeding System
● Multi-Disease Resistance		
● Reduced Stature Corn		

Other Crops

• Canola • Cotton • Millet • Mustard • Rice • Sorghum • Sunflower

/ Underpinned by world-class germplasm driving genetic gain

● **12 Technology Platforms**

Vylor

1. Estimated peak net trade revenue pipeline value by the end of 2039.

More value per R&D dollar: proven at Corteva, continue at Vylor

Realized **Corteva** returns from 2019 to 2025, and the forward pipeline value carried into **Vylor**, measured against major competitors

PROVEN

Corteva | 2019–2025

Revenue per $1 of seed R&D

$10.7

~1.9x peer average

Peer Average $5.6[1]

	Corteva	Peer Avg*
Seed revenue	**$61.6B**	$38.4B
R&D invested	**$5.8B**	$6.3B

CONTINUING

Vylor | Forward pipeline

Peak sales potential per $1 of seed R&D

~$19

~2.5x peer average

Peer Average ~$7.7[1]

	Vylor	Peer Avg*
Peak sales potential	**$18.7B**	$8.7B
R&D spend	**$1.0B**	$1.0B

[1]**Cumulative 2019–2025.** Peer R&D estimated from disclosed segment data. Peak sales potential are approximate estimates.
Peer average is calculated across 3 peers (Bayer, BASF & Syngenta): for each peer, seed revenue is divided by seed R&D to give that peer's ratio, and the 3 ratios are then averaged.
Peak sales potential are approximate estimates.
Peak sales potential is divided by current annual (2025) R&D to give that peer's ratio, and the 3 ratios are then averaged. The Peer mean column separately shows average peer peak sales potential and average peer R&D. This is a relative measure of pipeline value per unit of current R&D intensity, not a payback multiple: peak sales potential is realized over multiple years and reflects R&D invested across that period. Peer R&D is as reported or estimated from public disclosures; Peak revenue and sales potential is company-disclosed where available or estimated from public disclosures and internal analysis.

Vylor

Proprietary germplasm & advanced breeding creates sustained annual yield gains

ADVANCED TECHNOLOGIES

Industry-leading germplasm for 100+ years



Products launched (2025)	Products delivered (2020-2025)[1]
300+	1,700+

Accelerated Breeding

Advanced inbreds
1M

Automated seed processing
10M

Data Collection



Genetic insights
>10B

Digital field insights
>400M

Decision Making

AI model solutions
145

Genomic sequence data
>5 Pb[3]

SUSTAINED ANNUAL YIELD INCREASES

2015	2020	2025
PIONEER P1151 AM	PIONEER P1197 AM	PIONEER P13777 PCE
	RECORD SETTING	
	14 bu/A advantage	18 bu/A advantage

>30 bu/A[1] incremental yield in last decade

~$300[2] incremental bag value delivered in last decade

SUSTAINED ANNUAL YIELD INCREASES

2015	2020	2025
PIONEER P32T16R RR	PIONEER P33A53X RR2X	PIONEER P31Z03E Enlist E3
	3.9 bu/A advantage	4.4 bu/A advantage

>8 bu/A[1] incremental yield in last decade

~$90[2] incremental bag value delivered in last decade

Vylor captures approximately one-third of innovation value

Vylor

1. Source: Vylor and Vylor heritage company breeding data.
2. Incremental value estimated at 2.5 acres per bag of corn seed and $4/bu corn; and 1 acre per bag of soybean seed and $10.50/bu soybean.
3. Pb= Petabases

Expanding Vylor's sustained yield performance and advantage in the field

Sustained Yield Advantage

CORN

+6.3

bu/A

average yield advantage of Top 40 products over 2019-2025[1]

Win rate of 64% vs competition

Higher averages the last couple seasons

SOYBEAN



+2.9

bu/A

average yield advantage of Top 40 products over 2019-2025[2]

Win rate of 70% vs competition

Higher averages the last couple seasons

+

Proprietary Genetic Technology

CORN

Yield & Yield Stability (YYS)

- Industry's first biotech trait to improve yield and yield stability
- Delivers an average 3 bu/A yield increase[3]
- Some combinations have shown up to 10 bu/A yield advantage[3]



+3

bu/A

Yield average advantage in field trials across the Americas[3]

+

Gene Editing

CORN



Illustrative of technology advancement opportunity

+4–8

bu/A

average yield advantage in gene-edited hybrid trials[4]

Genetic performance & gene editing will double our annual yield improvement

1. Testing results from 154,489 total comparisons vs. competitors during crop years 2019-2025. Pioneer Top 40 corn hybrids in the U.S.
2. Testing results from 21,572 total comparisons vs competitors during crop years 2019-2025. Pioneer Top 40 soybean varieties in the U.S.
3. Testing results from 11 years of testing across 284 locations by environments in different hybrids.
4. Testing results from gene-edited trials during crop years 2024-2025 across 18 locations.

Hybrid wheat system enables new value for farmers, new core crop for Vylor

NEW VALUE – Vylor's proprietary technology unlocks productivity potential under normal and stressed conditions

HYBRID WHEAT OPPORTUNITY:

XPEDITE™ HYBRID WHEAT BREEDING SYSTEM

North America Launches[1]:

- Hard Red Winter in 2027
- Soft Red Winter in 2029
- Hard Red Spring in 2030

Global Applicability:

- System enables geographic expansion

~550M

acres of wheat produced globally



VALUE TO FARMERS:

>10%

Increase yield potential compared to leading varieties[2]

Up to

20%

Increase yield potential in water stressed conditions[3]

HYBRID WHEAT BREEDING SYSTEM:

- Breakthrough proprietary technology
- Performs in all environments and geographies[2, 3]
- Enables high-value, globally scalable seed platform
- Breeding underway in Europe and India

Vylor vs. Others	Vylor Advantage
Hybrid system	Native genetics + gene editing
Environmental response	Stable
Genetic gain	Faster
Germplasm compatibility	Works in all germplasm tested[2,3]
Cost of goods	Favorable
Additional agronomic requirements	None

TESTING AT SCALE IN THE FIELD

Vylor

1. Launch pending applicable completion of field testing.
2. Internal yield testing on pending launch hybrids: 3 years (2024, 2025, 2026) of testing with 41 locations in KS, NE, CO, & OK.
3. Internal yield testing on pending launch hybrids in stressed environments: 3 years (2024, 2025, 2026) of testing with 20 locations in KS, NE, CO & OK.
4. Map Wheat | USDA Foreign Agricultural Service

Vylor set to launch seven corn technology platforms in the next decade[1]

Industry leading technology solving insect, weed, disease, & extreme weather problems; unlocking higher yield

Seven corn technology platforms are worth $6–$7B[3]

Base technology platforms by region

NORTH AMERICA

Next Gen Above NA
This Decade
(PowerCore® Replacement)

- Broad-spectrum above-ground insect control including lepidoptera
- Long-term durability
- Multiple herbicide tolerances

Next Gen Above / Below NA
Early Next Decade
(Vorceed® & Qrome® Replacement)

- Broad-spectrum above-and below-ground insect protection including lepidopteran and corn root worm
- Two new proprietary non-Bt[2] modes of action
- Multiple herbicide tolerances

LATIN AMERICA

ABRANVO™
This Decade
(PowerCore® Ultra Replacement)

- Broad-spectrum lepidopteran control including fall armyworm
- Two new proprietary modes of action for insect control
- Multiple herbicide tolerances

Next Gen Above LA
Mid-Next Decade
(ABRANVO™ Replacement)

- Broad-spectrum lepidopteran control including fall armyworm
- Two new proprietary modes of action for insect control
- Multiple herbicide tolerances

Leveraged Technology Platforms

YIELD & YIELD STABILITY
- Enhanced yield potential

MULTI-DISEASE RESISTANCE
- Simplified disease management

REDUCED STATURE CORN
- Extreme weather resilience

PLATFORMS UNLOCK GROWTH POTENTIAL FOR VYLOR THROUGHOUT NEXT DECADE

- Elite germplasm
- Proprietary, royalty advantaged
- Licensing enabled

Vylor

1. Launch pending applicable global regulatory reviews and completion of field testing.
2. Bacillus thuringiensis
3. Estimated 2039 Peak NTR

Vylor set to launch four soybean technology platforms in the next decade[1]

Industry leading platforms solving pest and disease problems; unlocking higher yield

Four soybean technology platforms are worth $3B–$3.5B[3]

NORTH AMERICA

Novel Herbicide Tolerance Portfolio
This Decade – Mid-Next Decade
(Builds beyond Enlist E3® Soybeans[2])

- Builds beyond the proven Enlist E3® soybeans weed-control foundation
- Expand weed-control flexibility through novel trait stacks with additional herbicide tolerance MOAs
- Next Gen herbicide tolerance expands weed-control optionality through additional MOAs

LATIN AMERICA

ACCELERATED LAUNCH

Next Gen Lepidopteran
Early Next Decade
(Conkesta E3® Replacement)

- Broadest-spectrum insect control on the market including fall armyworm and other LA pests
- 3 new novel proprietary MOA for lepidopteran control
- Weed-control flexibility through additional herbicide tolerance MOAs

1st Gen Asian Soybean Rust
Mid-Next Decade

- Industry first transgenic Asian soybean rust resistance trait for Brazil/LA
- Highly effective with excellent agronomics to protect yield
- Complements Multi-Disease Resistance for broader disease control of key targets

Leveraged Technology Platforms

MULTI-DISEASE RESISTANCE
- Simplified disease management

SOYBEAN PORTFOLIO POISED FOR DIFFERENTIATING YIELD & YIELD PROTECTION

- Elite germplasm
- Proprietary, royalty advantaged
- Licensing enabled

Vylor

1. Launch pending applicable global regulatory reviews and completion of field testing.
2. The transgenic soybean event in Enlist E3® soybeans is jointly developed and owned by Corteva Agriscience and M.S. Technologies, L.L.C.
3. Estimated 2039 Peak NTR

Vylor's industry-leading gene editing position & Genlytix™ ecosystem[1] expands growth opportunity

GROWING VALUE

Expanding global opportunity



NEW: AI-driven innovation

SCALE	**~20M**	gene modifications predicted across hundreds of corn lines
SPEED	**<2 days**	to generate megaplexed design
ACCURACY	**94%[3]**	accuracy in predicting expression changes

Accelerating our leadership since 2024

- Added 6 crop species
- Doubled gene targets
- Expanded editing of elite lines
- Increased edited plants by 20%
- World's largest IP portfolio in ag
- Doubled external collaborations

Vylor Edge[4]
External investments expanding technology platform and product delivery across crops and geographies

The industry-leading gene editing ecosystem to accelerate sustainable agriculture



1. Data shown represents the total cumulative number across each category.
2. Number encompasses products, concepts and technologies.
3. When predicting significant change in gene expression direction in AI-designed gene edits leveraging Large Language Models (LLMS) or Foundation Models.
4. For more information on Vylor Edge, please reference the Sept. 3, 2026, press release.

Vylor set to double annual yield improvement with gene editing in elite germplasm

WORLD CLASS BREEDING ENGINE		VYLOR'S ADVANTAGE FOR GENE EDITING	
Industry-leading germplasm pool		1M lines	• Unmatched elite global germplasm performance
Elite plant transformation		1000's Elite Lines	• Gene editing possible in elite pipeline of new lines
Global & local field testing		>12M Plots	• Global network to test and select best gene edits
World class automated phenotyping		>400M Insights	• Advanced tech enables rapid evaluation and advancement
Characterization & agronomy		145 AI Models	• Advanced design and selection using global data
Superior Products			

Improves yield: 4-8 bu/A[1]

Kernel row number

Improves standability: 30% height reduction

Stature

Bridges geographies: Expands 2-3 RM zones



Relative Maturity

Relative Maturity

Advancements in gene-edited breeding doubles annual yield improvement

1. Testing results from gene-edited trials during crop years 2024-2025 across 18 locations.

Vylor's gene editing advancements set to simplify disease management

Better disease management in cropping systems helps farmers protect yield

Foundational advantage
Deep pipeline focused on new discoveries and durability

- Global germplasm pool with >90K corn lines enable wide screening for disease research
- 3.3 Pb[2] genomics sequence data unlocks performance insights
- Industry-leading phenotyping of 35 corn and soybean diseases

Growing Pipeline of Genes
20+

1st Gen Multi-Disease Resistance Corn



- Protects yield against
  - Northern Corn Leaf Blight
  - Gray Leaf Spot
  - Southern Rust
  - Anthracnose Stalk Rot
- Excellent yield performance
- Target markets of NA, LATAM, and EU

PROTECTS YIELD: up to 20%[3]



1st Gen Multi-Disease Resistance Soybean



- Novel disease management solution
- Targets:
  - Soybean Cyst Nematode
  - Phytophthora Root Rot
  - Root-Knot Nematode

Leverageable across other crops



ADJACENT MARKETS
Fruits and Vegetables
Trees, Nuts, and Vines

1. Stewarded advanced trials. Launch pending applicable global regulatory reviews and completion of field testing
2. Pb= Petabases
3. Based on 2025 field testing results under high Southern Rust testing conditions

Vylor's leadership in innovation, proprietary solutions underpin strong value and growth opportunities

Growing value

12 New technology platforms launching in the next decade — the Largest in the Industry

~$19B Estimated peak net trade revenue[1]

~$19 Best ROI per dollar invested

Vylor's innovation differentiators

Gene editing
Industry-leading position in gene editing, Genlytix™ ecosystem extends performance and expands where to play

Biotechnology
Proprietary portfolio of technologies extends leadership and expands licensing opportunity

Breeding
Industry-leading advantaged germplasm delivers sustained annual performance advantage, unlocks new value in crops

Vylor

1. Estimated peak net trade revenue pipeline value by the end of 2039.

Vylor

A closer look at our seed business

Judd O'Connor

CHIEF COMMERCIAL AND OPERATIONS OFFICER



Unlocking a meaningfully larger opportunity

Vylor's seed and genetics expands our addressable market well beyond existing value pool

2025

~$60B

TRADITIONAL ROW CROP SEED MARKET[1]

Strong demand for crop outputs resulting in consistent planted area

Farmers prioritize seed performance leading to resilient low single digit pricing growth

2035E

~$75B

TRADITIONAL ROW CROP SEED MARKET[1]

Above market growth through:

- New traits
- New geographies
- Licensing

Additional expanded opportunities:

- Hybrid wheat value creation
- Gene editing shifting value upstream into genetics
- Adjacent genetics opportunities

Vylor

1. Market based on grower-level value including branded business and out-licensing revenue.

Our end-to-end operating model sets Vylor apart

Creating value with a farmer focused mindset

Vylor™ One Seed

Value for farmers

- Innovative pipeline with competitive products to meet farmers' evolving needs globally
- Increased yields, year after year
- Consistent, high-quality reliable seed

Value for Vylor

- Leading brand position - #1 or 2 in key markets
- Value-based pricing through differentiation
- High returns on invested capital
- Recurring revenue model with attractive margins



Vylor

Seed operations network: quality, reliable supply at scale

Seed production process optimized through automation and AI

FIELD ACTIVITIES

- Planting
- Field management
- Harvest
- Stabilization

FOCUS
Quality and productivity per acre for reliable supply

PLANT ACTIVITIES

- Conditioning
- Treat & pack
- Warehouse
- Distribution

FOCUS
Scale, productivity and efficient delivery

60 production sites

R&D

137 sites
30+ countries
3,000+ employees

FIELD NETWORK

19,000 growers
40,000+ fields
1.5 million+ acres

PRODUCTION

100 million+ unit capacity[1]
30 countries
4,500+ employees

Scaled, locally executed operations enable reliable supply, margin consistency, and future growth

1. Capacity inclusive of Vylor internal and tollers.

Vylor

Comprehensive route-to-market based on customer segmentation and buying preferences

Enables a differentiated customer experience through industry-leading brand portfolio

FLAGSHIP PIONEER® BRAND GLOBALLY

PIONEER®
HUNDRED YEARS

High-touch experience with premium products and services

FULL-SERVICE RETAIL BRAND ~12 COUNTRIES

BREVANT seeds

Full-service retail, broad selection of high-quality inputs and services

REGIONAL & DISTRIBUTION BRANDS ~5 COUNTRIES

HOEGEMEYER
PhytoGen
NEXSEM
nord
MAÍCES HÍBRIDOS DUO
PANNAR
XL
AgVenture
VOLTIS
eluxe SEED
POWER PLUS

Local professional with local knowledge and experience

TRAIT AND GERMPLASM LICENSING[1] Vylor One

Enlist E3 SOYBEANS
Conkesta E3 SOJA Enlist
Nexera
QROME
Enlist CORN
POWERCORE Enlist
HERCULEX I HX
CORDIUS
WideStrike 3 INSECT PROTECTION
XPEDITE
ABRANVO™

Access from non-Vylor source

Deep customer relationships backed by performance and yield outcomes

Vylor

1. The transgenic soybean event in Enlist E3® and Conkesta E3® soybeans is jointly developed and owned by Corteva Agriscience and M.S. Technologies L.L.C.

Unlocking a new era in yield: 7 corn technology platforms in ten years fit 90% of Americas corn market

Leading position globally with 2025 Top 40 Products delivering 6.9 bu/A yield advantage[2] -- creates foundation for future launches



Differentiated product delivered in advantaged germplasm driving customer value through disciplined launch sequence

Validate and demonstrate in stewarded plots → Pilot and launch additional technologies → Scale and expand commercial launches

Strengthens our brands. Licensing enabled. Royalty advantaged. $2B in value by 2035.

Vylor

1. Pending applicable regulatory reviews and completion of field testing.
2. Pioneer® brand corn Top 40 products. Data is based on average of 2025 23,718 comparisons made in the United States through November 17, 2025. Comparisons are against all competitors, within +/- .3 RM of the competitive brand. Product responses are variable and subject to any number of environmental, disease and pest pressures. Individual results may vary.
3. Grower value, based on 2025 Kynetic Data.

Proven market leader at scale with elite germplasm in U.S. soybeans, unlocking growth in Latin America

NORTH AMERICA

Market leader with continued opportunity



- #1 HT soybean trait in U.S.[1]
- Proven revenue generator
- Positioned for continued leadership

Enlist E3 SOYBEANS

Delivering powerful technology

- Pioneer Z series delivers 3.4 bu/A advantage[2]; world record of 218 bu/A[3]
- Complete trait and herbicide system
- Investing to pave way for next gen herbicide tolerance and disease resistance through gene editing in mid-2030s[4]

Meeting farmers where they are

- Available in multiple Vylor brands and to over 100 licensees
- In >95% of Vylor branded products

LATIN AMERICA

Market leader with continued opportunity



- Latin America is Vylor's largest soybean growth opportunity
- Multiple Lepidopteran pests driving demand

Enlist E3 SOJA

Conkesta E3 SOJA Enlist

Delivering powerful technology

- Multiple modes of insect control
- Superior control of resistant and hard-to-control weeds and grasses
- Investing in next generation of superior insect control, herbicide, and disease control traits[4]



Meeting farmers where they are

- Broad trait licensing to leading genetic suppliers
- Multiplier networks enable ramp up of product licensing

CORDIUS

Leading genetic, innovative technology and winning go-to-market strategy—expand opportunities in the Americas

1. The transgenic soybean event in Enlist E3® soybeans and Conkesta E3® soybeans is jointly developed and owned by Corteva Agriscience and M.S. Technologies L.L.C.
2. Pioneer® brand Z-Series soybeans delivered a 3.4 bu/A yield advantage over all Enlist E3® competitors across 4,485 comparisons, providing an estimated $33 per-acre income advantage (based on $9.75/bu soybeans).
3. Alex Harrell of Leesburg, Georgia, set a new world record of 218.2856 bu/A with Pioneer® brand Z-Series variety P49Z02E™. Verified by the University of Georgia extension, Harrell broke his previous world record of 206 bu/A set in 2023.
4. Launch timelines pending applicable regulatory review.

Extending our corn & soy advantage across high-value regional crops

Vylor leverages our leading positions to capture additional value in key regional crops

>100 MILLION ACRES[1] OF OPPORTUNITY



Crop	Primary geography	Vylor position	Examples
WHEAT	U.S. & Canada	Hybrid wheat pre-launch	• Proven lineup of patented Soft Red Winter Wheat varieties with proprietary genetics and top performance • Applied R&D expertise to develop Xpedite™ Hybrid Wheat Breeding System to improve reliable, efficient production • Initial Hard Red Winter hybrid launch in 2027
SUNFLOWER	EU	#2	• Strengthening hybrid performance and farmer ROI to drive share gains in core markets (Black Sea, EU) • Protecting yield and farmer value with next gen downy mildew resistance and differentiated defensive trait package Leveraging our short /second season sunflowers for biofuels in Europe through Etlas
MUSTARD	India	#1	• Launched first herbicide tolerant mustard in 2026, high value oilseed crop in India Testing opportunities in biofuels across the Americas
CANOLA	Canada	#2	Capturing biofuel growth through breeding leadership—testing spring canola in Latin America and expanding winter canola in NA in partnership • Unlocking yield and reducing harvest risk through next-gen traits (e.g., pod shatter resistance)
COTTON	U.S.	#2	• Leading PhytoGen elite germplasm and breeding engine enables penetration across growing region • Cotton growth accelerated by strategic access and advanced traits, boosting competitiveness and market share: Widestrike® 3 Glyphosate Tolerant Enlist® Cotton available for licensing

Creating new market biofuel opportunities through partnerships

Focuses on high-value growth opportunities, maximizes ROI on R&D, strengthens farmer relationships

Vylor

1. Source: Vylor and Kynetec; US wheat and cotton, Canada canola, EU sunflower (excluding Russia), India mustard.

Licensing improves ROI, accelerates growth

Available through Vylor One

Strategic approach tailored by market—licensing growth in 2020s expanding rapidly in the 2030s

END OF 2020's: Technology access

- Superior soybean germplasm with leading Enlist E3® soybean technology available through 120+ licensees
- Expand partnerships & collaborations; secure freedom to operate
- Expand offer: PowerCore®; Qrome® corn products; ABRANVO™; Next Gen Above NA; Enlist® Cotton products; growing portfolio of finished lines

EARLY 2030's: Mix evolution

- Growing pipeline of proprietary technology and technology packages in corn
- Additional portfolio of commercial-ready finished products for licensing
- Gene editing enabled, Multi-Disease Resistance
- Expand offer: Hybrid Wheat; U.S. Enlist® Cotton trait; Next Gen HT Soybean; Next Gen Lep; Soybean germplasm offering

2035 AND BEYOND: Global expansion

- Extend market reach through targeted opportunities in Europe, Africa, and Asia Pacific
- Expand offer: Cotton Next Gen Lep; Xpedite™ Hybrid Wheat Breeding System; Additional germplasm/finished lines



Achieve a >$1B licensing income position by 2035 and generate annual licensing revenue of ~$2B by 2040[3]

1. The transgenic soybean event in Enlist E3® soybeans and Conkesta E3® soybeans is jointly developed and owned by Corteva Agriscience and M.S. Technologies L.L.C.
2. Vylor internal analysis.
3. $1B licensing income position and $2B licensing revenue across portfolios.

Proven seed and genetics engine with multiple paths to value creation

Proven core, a larger addressable market ahead, and multiple paths to compound growth over time

1. Innovation-driven products and solutions: world class R&D and proprietary germplasm delivering deep pipeline of proprietary technology

2. Global production network: global scale and operational excellence deliver reliable, high-quality seed

3. Commercial execution excellence: trusted relationships and superior insights drive adoption and value for farmers through established brands

4. Licensing and partnerships: expanding royalty and licensing opportunities to unlock future growth

Vylor

Break

Vylor

Financial model & long-term value creation

David Johnson
CHIEF FINANCIAL OFFICER

Setting the stage: 2026E net sales

Product sales[1] ($B)



+

Licensing sales[1] ($B)



=

Total sales[1] ($B)



Unrivaled route to market | Licensing margin expansion | Productivity cost advantage

Vylor

1. Represent management's forward-looking estimates and are presented on a pro forma basis giving effect to the transactions described in the Form 10. See slide 4 regarding forward-looking non-GAAP measures.

2026–2029 financial framework

Key assumptions

- Price-for-value strategy
- Increased licensing income
- Share gains in key markets
- Cost and productivity actions
- Targeting ~60% FCF conversion[1]



3–4% revenue CAGR, 7–8% Operating EBITDA CAGR reflects demand for technology and disciplined execution

1. Represent management's forward-looking estimates and are presented on a pro forma basis giving effect to the transactions described in the Form 10. 2025 and 2026 represent Adjusted pro forma Operating EBITDA. Operating EBITDA, Adjusted Pro Forma Operating EBITDA, Operating EBITDA Margin, and Adjusted Pro Forma Operating EBITDA Margin are non-GAAP financial measures. See slide 4 regarding forward-looking non-GAAP measures. See appendix for non-GAAP reconciliations.

Vylor

Market assumptions 2027–2029

Seed planted area stable versus 2026 outlook

Crop commodity prices remain relatively stable versus current

On-farm demand and competitive landscape remain steady

Consistency in global trade policy and export market accessibility

Constant currency versus 2027 outlook rates

Balanced market assumptions support EBITDA growth 2026–2029

Vylor

Straightforward 2029 growth algorithm

Key assumptions

LSD seed price and mix from new technology

>70% increase in licensing income vs. 2026

Elite germplasm on track to double genetic gain by 2035

Currency at 2027E constant rates



3–4% Revenue CAGR driven by core engines and licensing

1. Represents management's forward-looking estimates and is presented on a pro forma basis giving effect to the transactions described in the Form 10. See slide 4 regarding forward-looking non-GAAP measures.

Operating EBITDA growth outlook: 2026–2029

Key assumptions

- LSD seed price / mix from new technology
- >$200M EBITDA improvement in net licensing
- Benefits from productivity and cost actions offsetting incremental cost of production
- SG&A and R&D as a % of sales consistent with 2026E



7–8% Operating EBITDA CAGR driven by base business + licensing + operational excellence

1. Represent management's forward-looking estimates and are presented on a pro forma basis giving effect to the transactions described in the Form 10. 2025 and 2026 represent Adjusted pro forma Operating EBITDA. Operating EBITDA, Adjusted Pro Forma Operating EBITDA, Operating EBITDA Margin, and Adjusted Pro Forma Operating EBITDA Margin are non-GAAP financial measures. See slide 4 regarding forward-looking non-GAAP measures. See appendix for non-GAAP reconciliations.

Vylor

Exceptional business model of capturing value on innovation

PRICE/MIX TRENDS OVER TIME (% YOY GROWTH)

	2016-2025
Value capture	2–3% per year
Value equation	Elite germplasm yield gains + New products + New traits + licensing FTO

~$1B in annual R&D → LSD pricing
R&D is the engine to our compounding growth

Key drivers

- Seed pricing demonstrates durable value delivery and structural resilience, supporting consistent growth across commodity price cycles
- Commodity volatility contrasts with smoother and lagged seed pricing
- Seed yield remains a priority for farmers, underpinning pricing power and demand stability by improving farm-level economics and profitability
- The only farming input that has demonstrated consistent incremental value to the customer

Vylor

1. Represents global seed pricing (Source: Corteva internal analysis)

Licensing inflection

Licensing income driven by adoption of Enlist E3® soybeans and Conkesta E3® soybeans and PowerCore® Enlist® corn

~65% of US soy acres and >10% Brazil soy acres utilizing Enlist technology in 2026

>120 licensees

Triple stack corn launching in 2027 in U.S., contributing ~$40M by 2029



Transforming ~$700M net cost headwind in 2020 to net $1B profit engine by 2035

1. The transgenic soybean event in Enlist E3® soybeans and Conkesta E3® soybeans is jointly developed and owned by Corteva Agriscience and M.S. Technologies L.L.C.

Vylor seasonality based on annual business cycle

First half

- Northern Hemisphere selling season
  - Primarily NA and Europe
- Includes tail-end Brazil Safrinha season
- Seasonal debt builds
- Substantial net working capital outflow, driven by U.S. business model

Second half

- Southern Hemisphere selling season
  - Sales concentrated in LATAM, including majority of Brazil Safrinha season
  - Potential early shipments in NA
- Seasonal debt peaks and then is largely repaid
- Significant cash collections from receivables and prepay customers in December



1. 2025 Net sales are stated on an as reported basis for the Seed segment of Corteva.

Capital allocation strategy

Summary highlights

- Cumulative $5.5–$6.5B free cash flow[1]
- Strong BBB+ / Baa1 investment grade rating
- Intend to return ~$1B annually via disciplined share repurchases, absent strategic M&A
- Dividend grows over time in line with operating EBITDA
- Investing in R&D at ~10% of sales
- Targeting average FCF / EBITDA[1] ~60%

SOURCES AND USES OF CASH 2027–2029



Exceptional cash generation and disciplined deployment supporting growth and shareholder returns

1. Represent management's forward-looking estimates and are presented on a pro forma basis giving effect to the transactions described in the Form 10. Free Cash Flow and Free Cash Flow Conversion are non-GAAP financial measures. See slide 4 regarding forward-looking non-GAAP measures. See appendix for non-GAAP reconciliations.

Strategic M&A priorities

Focused, disciplined approach

KEY AREAS OF FOCUS	OUR M&A APPROACH	FINANCIAL CRITERIA
Wheat	Targeted & capability-driven	Above-market revenue growth
Gene editing technology	Return-focused investments	Value creation and returns > hurdle rate
Adjacent crops	Disciplined valuation criteria	



Enhancing our innovation pipeline & growth potential

Vylor

Financial highlights

	2027-2029 GOALS	VALUE DRIVERS
Top-line growth driven by pipeline innovation	**3–4% revenue[1] CAGR[2]**	Innovation pipeline and licensing platform position Vylor for durable, above-market growth
Earnings growth and margin expansion	**7–8% EBITDA[1] CAGR[2]** **~300bps EBITDA margin[1] expansion[2]**	Licensing inflection, pricing power, and productivity expand EBITDA margins to ~30%
Disciplined capital allocation	**Capex ~4% of sales**	Strong free cash flow funds growth investments while supporting dividends and buybacks
Seasonality	**Strong liquidity**	Predictable seasonality is supported by liquidity, customer financing, and strong collections

Strong execution, consistent investment, and commitment to capital returns create long-term shareholder value

Vylor

1. Represent management's forward-looking estimates and are presented on a pro forma basis giving effect to the transactions described in the Form 10. Operating EBITDA and Operating EBITDA margin are non-GAAP financial measures. See slide 4 regarding forward-looking non-GAAP measures.
2. At midpoint.

Q&A session

Vylor

Closing remarks

Chuck Magro

CHIEF EXECUTIVE OFFICER

Why invest with us?

1. Leadership in well-structured market
2. World-class germplasm and breeding
3. Unparalleled farmer relationships
4. Licensing expands reach and returns
5. New value pools: gene editing, wheat, and biofuels
6. Strong earnings, margins, and cash flow growth
7. Proven, high-performing management team

Vylor

Appendix

Reconciliation of Pro Forma Income (Loss) from Continuing Operations to Pro Forma Operating EBITDA and Adjusted Pro Forma Operating EBITDA

	2025	
	($ in Millions)	*Margin %* [4]
Pro forma Income (loss) from continuing operations after income taxes (GAAP)[1]	$325	3.2%
Provision for (benefit from) income taxes on continuing operations	275	2.7%
Pro forma Income (loss) from continuing operations before income taxes (GAAP)[1]	$600	6.0%
Depreciation and amortization	781	7.8%
Interest - net	125	1.2%
Exchange (gains) losses - net	143	1.4%
Non-operating (benefits) costs - net	3	0.0%
Significant items (benefit) charge	650	6.5%
Separation costs	201	2.0%
Pro forma Operating EBITDA / EBITDA Margin (Non-GAAP)	$2,503	24.9%
Management adjustments [2,3]	75	0.7%
Adjusted Pro Forma Operating EBITDA / EBITDA Margin (Non-GAAP)	$2,578	25.6%

1. Source: Amended Form 10 filed September14, 2026.
2. Historical financial statements include expense allocations for certain corporate functions performed on our behalf by Corteva, including information technology, finance, executive, human resources and legal. As a standalone public company, we expect that the costs we incur on a standalone basis for such expenses previously allocated to us by Corteva and new costs relating to our public company reporting and compliance obligations will be less than the expense allocations from Corteva within our historical financial statements. The costs of Vylor we plan to incur are based on our expected organizational structure and expected cost structure as a standalone company. In order to determine the impact of the synergies and dis-synergies, Vylor prepared a detailed assessment of personnel costs based on the estimated resources and associated costs required as a baseline to stand up as a standalone company. Vylor also includes incremental tax expense as a result of cost savings, separation costs, and additional depreciation and amortization.
3. Vylor identified cost savings of $58 million for the year ended December 31, 2025 associated with the allocation of costs by Corteva. The net impact of the cost savings and the separation costs of $23 million resulted in incremental tax expense of $8 million and a net increase to pro forma income (loss) after income taxes from continuing operations of $27 million. Vylor also included additional depreciation and amortization of $17 million for the year ended December 31, 2025.
4. The EBITDA margin percentages are determined by dividing amounts in the table above for the for the twelve months ended December 31, 2025 by pro forma net sales of $10,067 million. Margin percentages may not foot, due to rounding.

Vylor

Important Notices

™® Trademarks of Corteva Agriscience or its affiliated companies.

The transgenic soybean event in Conkesta E3® soybeans and Enlist E3® soybeans is jointly developed and owned by Corteva Agriscience and M.S. Technologies L.L.C. Enlist Duo® and Enlist One® herbicides are not registered for sale or use in all states or counties. Contact your state pesticide regulatory agency to determine if a product is registered for sale or use in your area. Enlist Duo and Enlist One are the only 2,4-D products authorized for use with Enlist crops. Consult Enlist herbicide labels for weed species controlled. ALWAYS READ AND FOLLOW PESTICIDE LABEL DIRECTIONS. IT IS A VIOLATION OF FEDERAL AND STATE LAW TO USE ANY PESTICIDE PRODUCT OTHER THAN IN ACCORDANCE WITH ITS LABELING . ONLY USE FORMULATIONS THAT ARE SPECIFICALLY LABELED FOR SUCH USE IN THE STATE OF APPLICATION . USE OF PESTICIDE PRODUCTS, INCLUDING, WITHOUT LIMITATION, 2,4-D-CONTAINING PRODUCTS NOT AUTHORIZED FOR USE WITH ENLIST CROPS, MAY RESULT IN OFF-TARGET DAMAGE TO SENSITIVE CROPS/AREAS AND/OR SUSCEPTIBLE PLANTS, IN ADDITION TO CIVIL AND/OR CRIMINAL PENALTIES. Additional product-specific stewardship requirements for Enlist crops, including the Enlist Product Use Guide, can be found at www.traitstewardship.com.

Plenish® high oleic soybeans have an enhanced oil profile and are produced and channeled under contract to specific grain markets. Growers should refer to the Product Use Guide on www.corteva.us/resources/trait-stewardship.html for more information all Corteva seed products.

SmartStax® multi-event technology developed by Corteva Agriscience and Monsanto. ®SmartStax and the SmartStax Logo are registered trademarks of Bayer Group. POWERCORE® multi-event technology developed by Corteva Agriscience and Monsanto. ®Roundup and Roundup Ready, Roundup Ready 2 Xtend®, and Roundup Ready 2 Yield® are registered trademarks of Bayer Group, used under license. is a trademark of Bayer group. Roundup Ready® crops contain genes that confer tolerance to glyphosate, the active ingredient in Roundup® brand agricultural herbicides. Roundup® brand agricultural herbicides will kill crops that are not tolerant to glyphosate.

LibertyLink® and the Water Droplet Design are registered trademarks of BASF.

Agrisure Viptera® is a registered trademark of, and used under license from, a Syngenta Group Company. Agrisure® technology incorporated into these seeds is commercialized under a license from Syngenta Crop Protection AG.

The unique Clearfield symbol, Clearfield® Hybrids and varieties with the CLEARFIELD® trait (CL) are tolerant to labeled rates of Beyond®, Odyssey® or Absolute® herbicides. This technology allows for post-emergent applications of these herbicides without crop injury or stress (see herbicide label). Labeled herbicides should only be used over the top of those hybrids and varieties that contain the CLEARFIELD trait.

Brevant® seeds Nexera® canola are grown and marketed under identity-preserved programs.

Varieties with the Glyphosate Tolerant trait (including those designated by the letter "R" in the product number) contain genes that confer tolerance to glyphosate herbicides. Glyphosate herbicides will kill crops that are not tolerant to glyphosate.

Hybrids with the Inzen™ trait are resistant to Zest™ WDG herbicide. The Inzen™ grain sorghum trait is not yet available for commercial sale or commercial planting.

Propound™ advanced canola meal will not be offered for sale or distribution until completion of field testing and applicable regulatory reviews.

Always follow IRM, grain marketing and all other stewardship practices and pesticide label directions. B.t. products may not yet be registered in all states. Check with your seed representative for the registration status in your state. Corteva Agriscience is a member of Excellence Through Stewardship® (ETS). Corteva Agriscience products are commercialized in accordance with ETS Product Launch Stewardship Guidance and in compliance with the Corteva Agriscience policies regarding stewardship of those products. In line with these guidelines, our product launch process for responsible launches of new products includes a longstanding process to evaluate export market information, value chain consultations, and regulatory functionality. Growers and end-users must take all steps within their control to follow appropriate stewardship requirements and confirm their buyer's acceptance of the grain or other material being purchased. For more detailed information on the status of a trait or stack, please visit www.biotradestatus.com. Excellence Through Stewardship® is a registered trademark of Excellence Through Stewardship. Always read and follow label directions.

© 2026 Corteva

Vylor